Max Healthcare Institute Ltd. News and Updates

Name: Latest research reports of Max Healthcare Institute Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Max Healthcare Institute Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Max Healthcare Institute Ltd. from all sources in a single place.

Max Healthcare Institute Ltd.

28 Oct 2025

1135.70

-1.05%

Max Healthcare's 10,000-bed expansion built with zero debt: MD Abhay Soi

Business Standard

Max Healthcare's 6,000 crore plan to add 10,000 beds over four years will be fully funded through internal accruals, says CMD Abhay Soi, outlining a strategy for growth without margin dilution

Max Healthcare Institute Ltd.'s price crossed below 50Day SMA today

Max Healthcare Institute Ltd.

07 Oct 2025

1135.70

-1.05%

'Buy' Max Healthcare Shares Says Motilal Oswal On Positive Growth Triggers Check Target Price

NDTV Profit

Max also has a proven track record of considerably improving the performance of acquired assets, thereby providing an additional growth lever going forward as well, adds the brokerage.

Max Healthcare Institute Ltd.'s price crossed below 50Day SMA today

Max Healthcare Institute Ltd.

09 Sep 2025

1135.70

-1.05%

Max Healthcare Rated Bew 'Buy' At Nuvama Check Target Price

NDTV Profit

Max Healthcare is strategically located in high-growth areas, as the company is focused on super-speciality care in metros and top-tier urban clusters.

Max Healthcare Institute Ltd. is trading below all available SMAs

Max Healthcare gets new 'Buy' call from Nuvama; target hints at new high

Business Standard | 09 Sep 2025

Max Healthcare Institute Ltd.

02 Sep 2025, 12:00AM

1135.70

-1.05%

MAX HEALTHCARE INSTITUTE LIMITED

Hold: Max Healthcare Institute Ltd.

Target

Geojit BNP Paribas

The company's impressive Q1FY26 performance, which saw robust revenue growth, was fuelled by higher occupancy rates and ARPOB. This in turn led to an expansion in margins and profitability. The company's ambitious expansion plan to double its capacity over the next 4-5 years remain on track, with plans to add approximately 1,000 brownfield and 500 greenfield beds. The healthy growth and occupancy trends observed in the existing and recently acquired units further reinforce the positive outlook. The stock is trading at elevated valuations therefore we downgrade...

Number of FII/FPI investors decreased from 1145 to 1089 in Sep 2025 qtr

Max Healthcare Institute Ltd.

24 Aug 2025

1135.70

-1.05%

Hospitals To Suspend Cashless Services For Bajaj Allianz Policyholders From Sept. 1

NDTV Profit

This development is crucial as over 15,000 member hospitals including Max Healthcare and Medanta, which would now stop cashless treatment by Bajaj Allianz.

Max Healthcare Insti.. has an average target of 1305.00 from 6 brokers.

Max Healthcare Institute Ltd.

18 Aug 2025

1135.70

-1.05%

'Buy' Max Healthcare Shares Maintains PL Capital Post Inline Q1 Results Check Target Price

NDTV Profit

Max Healthcare's operational efficiency has also been commendable, especially in competitive markets like NCR, adds the brokerage.

Number of FII/FPI investors decreased from 1145 to 1089 in Sep 2025 qtr

Max Healthcare Institute Ltd.

18 Aug 2025

1135.70

-1.05%

Result Update:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock with a TP of Rs 1,450/share, implying an upside potential of 19% from the CMP.

Max Healthcare Institute Ltd.'s price crossed below 30Day SMA today

Max Healthcare Institute Ltd.

14 Aug 2025

1135.70

-1.05%

Max Healthcare Institute Results Earnings Call for Q1FY26

Conference Call with Max Healthcare Institute Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Max Healthcare Institute Ltd.

14 Aug 2025

1135.70

-1.05%

Max Healthcare Institute (MAXHEALT IN) Q1FY26 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Max Healthcare Institute (MAXHEALT) reported healthy EBITDA growth of 23% YoY to Rs 6.14bn; in line with our estimates. The company showed phenomenal growth with ~19% EBITDA CAGR over FY22-25. We expect pick-up in the growth momentum given 1) strong expansion plans (+3700 additional beds over FY25-28E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and Noida. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY26E/27E...